logo
Chilco River Holdings Enters Premium Alcohol Beverage Sector, Targets Strategic Acquisitions to Accelerate Growth

Chilco River Holdings Enters Premium Alcohol Beverage Sector, Targets Strategic Acquisitions to Accelerate Growth

Chatsworth, California--(Newsfile Corp. - May 29, 2025) - Chilco River Holdings, Inc. (OTC Pink: CRVH) ('Chilco' or the 'Company'), a rising force in brand acceleration, is thrilled to announce a transformative leap into the booming premium alcoholic beverage industry. This bold pivot marks the beginning of an ambitious growth strategy centered on acquiring standout brands and building a powerhouse portfolio in one of the most dynamic consumer markets.
The company is currently engaged in advanced negotiations with multiple acquisition targets including innovative upstarts and established premium labels. Chilco is positioning itself at the forefront of a surging industry driven by demand for craft spirits, ready-to-drink cocktails (RTDs), and luxury lifestyle beverages.
'The premium beverage space is exploding with opportunity,' stated, Chief Executive Officer, William Lovett. 'Our entry into this market is a game-changer, and we're already in deep discussions with brands that we believe can supercharge our trajectory and deliver lasting value to our shareholders.'
As part of this strategic realignment, the Company has formally canceled prior agreements with Leuffer Desarrollos SA de CV, American Hemp Brands, Inc., and L Myers Associates. These transactions were never consummated and no longer reflect the Company's core business objectives. This provides a fresh start and allows Chilco to dedicate full resources and strategic efforts toward the premium alcohol sector.
'This marks a clean slate and a bold new direction for Chilco,' continued Lovett. 'The premium beverage space is full of energy and opportunity, and we are excited to dive in. With the right strategy and execution, we believe we can build something truly impactful for our shareholders.'
In parallel with its renewed business direction, Chilco is proud to announce it has achieved Pink Current Information status with OTC Markets. This milestone not only underscores the Company's commitment to transparency but also unlocks powerful new levers for growth, including M&A activity, capital raising, and the onboarding of top-tier leadership.
With a clear vision and renewed focus, Chilco River Holdings is moving forward with determination and purpose. The Company is committed to transparency, disciplined execution, and consistent communication with shareholders. As it enters the premium alcohol space, Chilco is well-positioned to seize new opportunities and build lasting value in one of today's most dynamic markets.
About Chilco River Holdings, Inc.
Chilco River Holdings is a U.S.-based brand accelerator focused on identifying and acquiring premium consumer products with high-growth potential. The Company is currently targeting acquisitions in the premium alcohol beverage sector, including spirits, and ready-to-drink brands.
For more information, please contact:
Investor Relations
Chilco River Holdings, Inc.
Email: [email protected]
Website: www.chilcoriver.com
Forward-Looking Statements:
This press release contains forward-looking statements, including statements regarding the Company's strategic direction, acquisition plans, and anticipated growth. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially due to factors such as market conditions, due diligence outcomes, and regulatory approvals. Chilco River Holdings undertakes no obligation to update these statements, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253741

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Yahoo

timean hour ago

  • Yahoo

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

Business Wire

timean hour ago

  • Business Wire

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Yahoo

timean hour ago

  • Yahoo

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the 'Common Stock'), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol 'ERNA.' The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308. As a result of the reverse stock split, every 15 shares of the Company's Common Stock issued and outstanding will be automatically reclassified into one new share of Common Stock. The reverse stock split will not modify any rights or preferences of the shares of the Company's Common Stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, and warrants, as well as to the number of shares issued and issuable under the Company's equity incentive plans. The Common Stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Common Stock or the par value of the Common Stock. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 2, 2025 at a ratio in the range of 1-for-10 to 1-for-15, such ratio to be determined by the Board of Directors. The Company's Board of Directors approved the reverse stock split at the ratio of 1-for-15. No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares. Stockholders who otherwise would have held a fractional share after giving effect to the reverse stock split will instead own one whole share of the post-reverse stock split Common Stock. As of the date of this press release, the Company had 110,418,022 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 7,361,201 shares of Common Stock issued and outstanding on a split-adjusted basis, without giving effect to any rounding for fractional shares. Computershare Inc. and its affiliate Computershare Trust Company, N.A., the Company's transfer agent (collectively, 'Computershare'), will act as the exchange agent for the reverse stock split. Stockholders of record holding certificates representing pre-split shares of the Company's Common Stock will receive a letter of transmittal from Computershare with instructions on how to surrender certificates representing pre-split shares. Stockholders should not send in their pre-split certificates until they receive a letter of transmittal from Computershare. Stockholders with book-entry shares or who hold their shares through a bank, broker, or other nominee will not need to take any action. Stockholders of record who held pre-split certificates will receive their post-split shares in book-entry form and will receive a statement from Computershare regarding their Common Stock ownership post-reverse stock split. Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the 'SEC') on April 14, 2025, which is available at and on the Company's website at Alongside Ernexa's recent financings and corporate restructuring, the Company believes this reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs. About Ernexa Therapeutics Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to the impact of the reverse stock split. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store